Ischemic heart disease (IHD) and adverse events after coronary stent placement represent polygenic disorders. They correspond to complex traits induced not only by multiple genes but also by the interaction of these genes with the environment. Multiple loci likely to be implicated in IHD are polymorphic, such that there are two or more variant forms of the gene in the population. These variants have been created by mutations that can change the coding sequence of the gene in question. A missense mutation, for example, would produce a different form of the encoded protein, whose function might be slightly altered compared
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with the ancestor protein. Alternatively, the mutation, might fall within the regulatory domains of a gene, thereby changing the level of expression of the gene product and/or when and where the gene is being activated. The specific impact of such mutations is further dependent on a variety of factors, both genetic and environmental.
The platelet antigen 2 (Pl A2 ) polymorphism represents one such variant that has been implicated in arterial thrombosis (1) (2) (3) . Due to the substitution of a cytosine for a thymidine at position 1565 in exon 2 of the glycoprotein IIIa (GPIIIa or integrin Beta 3 ) gene, the Pl A2 variant displays a proline instead of a leucine at amino acid 33 (4) . Hence, the ancestor gene is called Pl A1 and the variant gene Pl A2 , such that individuals can be Pl A1/A1 homozygous, Pl A1/A2 heterozygous or Pl A2/A2 homozygous. Glycoprotein IIIa, together with GPIIb, constitutes the fibrinogen receptor (GPIIb-IIIa), whose engagement represents the final common pathway for platelet activation (5) . Therefore, GPIIIa with its Pl A2 polymorphism is positioned as a candidate gene that contributes to arterial thromboembolic complications. The Pl A2 polymorphism affects the structure of GPIIb-IIIa, an assumption that was supported by the discovery of the Pl A2 variant as the cause for a severe form of neonatal alloimmune thrombocytopenia.
We initially observed a high prevalence of Pl A2 positivity in a population of siblings of patients with a history of premature IHD (IHD manifestations before age 60) (6) and in patients with severe unstable coronary syndromes (7) . In complex traits, it is unlikely that individual genes have an effect that would account for more than a few percent of the variance. Consistent with this concept, in a meta-analysis, we have found that the relative risk of myocardial infarction (MI) associated with Pl A2 is small (1.2) but significant (p ϭ 0.034) (8) . Several studies have not confirmed the association between Pl A2 and MI, in particular, the Physicians' Health Study (9) . Hence, as a consequence of such discrepancy among well conducted epidemiological studies, the link between Pl A2 and spontaneous MI is perceived as controversial (2) . In contrast with epidemiological data, most studies on the molecular effect of the Pl A2 polymorphism on GPIIb-IIIa function have been consistent. These studies have shown that the L33P mutation results in increased platelet responsiveness (10, 11) .
Genetic factors can influence illnesses in very specific ways. Considering that a clinical diagnosis of MI encompasses a complex phenotype, the relative impact of the Pl A2 polymorphism on MI may vary according to multiple factors, including the presence or absence of ST elevation, associated diseases like diabetes, gender, age, environment and medications. Studies of patients who have died suddenly and at a young age can be highly instructive, as the culprit lesion can be identified and characterized, and the number of contributing modifiers is often limited. Indeed, sudden death is a prominent first manifestation of coronary artery disease in younger individuals, such that sudden death victims do not have the opportunity to benefit from drugs that could interfere with the effect of a gene variant. Mikkelsson et al. (12) have reported that the prevalence of Pl A2 is elevated in sudden death victims whose coronary vessels contain a thrombus. They also reported that Pl A1/A1 homozygous individuals have a heightened atherosclerotic plaque burden compared with their Pl A2 counterparts. These results suggest that Pl A2 , in conjunction with other genetic and environmental risk factors, might contribute to driving the course of atherosclerosis toward a path of coronary plaque rupture and thrombus formation.
ENDOVASCULAR CORONARY PROCEDURES AND Pl

A2
Catheter-based intervention with stent placement has become a preferred management for patients with symptomatic coronary disease (both acute coronary ischemic syndromes and acute MI). Although associated with a risk that is not negligible, the procedure has become safer because of technological advances and the availability of powerful From the Heart and Lung Institute and Division of Cardiology, Department ofantithrombotic drugs (13) . The use of intracoronary stents has improved the immediate and short-term efficacy of endovascular procedures by maximizing acute procedural luminal gain and reducing the unfavorable geometric vascular remodeling of stenotic coronary vessels. We have hypothesized that, to be efficient, an antithrombotic strategy must target the impact of specific susceptibility genes implicated in coronary thrombosis under various clinical circumstances (14) . This principle is pertinent to strategies directed towards minimizing thromboembolic complications after stent revascularization. Platelet antigen 2 was the first platelet polymorphism implicated in thromboembolic complications associated with stent placement (15) . Several classes of drugs are clinically utilized to reduce platelet activity during coronary stenting: 1) acetylsalicylate (ASA), 2) thrombin antagonists (unfractionated heparin, mainly), 3) thienopyridine derivatives (clopidogrel and ticlopidine), and 4) GPIIb-IIIa antagonists (ReoPro or abciximab, Tirofiban or aggrastat, and Integrilin or eptafibitide). The role of dipyridamole for stent patients has not yet been established but could be of interest for drug combination strategies. Two combinations of drugs have been highly successful in reducing adverse events associated with coronary stent placement: a) ASA plus an antithrombin plus a thienopyridine derivative or b) aspirin plus an antithrombin plus a GPII-IIIa blocker. It is likely that the multidrug approach has the potential of covering a larger number of "thrombotic susceptibility genes" compared with single agent therapy. Experiments performed in vitro have consistently shown an increased responsiveness to agonists of platelets displaying the Pl A2 polymorphism (10, 11) . In this context, the study of Kastrati et al. (17) published in this issue can be viewed as investigating whether standard antithrombotic strategies have reached a sufficient level of control for the thrombotic diathesis conferred by the Pl A2 polymorphism.
Pl A2 AND ADVERSE EVENTS AFTER STENT PLACEMENT
There have been three studies published on the topic of Pl A2 and adverse events after stent revascularization. Walter et al. (15) studied 318 consecutive patients who received a coronary stent for indications of dissection, acute occlusion or suboptimal angioplasty. The primary end points of death, MI, stent thrombosis and coronary bypass surgery were followed over a period of 30 days after stent placement. All patients received aspirin and heparin during the procedure. Ticlopidine, 250 mg per day, was started and given for the next four weeks, in combination with aspirin (100 mg per day), which was continued indefinitely. Occlusion of the stent vessel was more frequent in Pl A2 positive individuals (9.5% in Pl A2 positive patients vs. From the analysis of these three studies that surveyed 2,357 patients for a period of 30 days, one may conclude that the Pl A2 polymorphism of GPIIIa represents a risk factor for adverse events in patients undergoing coronary stenting. Although all three studies were conducted by expert investigators, they differ in their complication rates and in their conclusion relative to the strength of the impact of Pl A2 on adverse events. Although some unrecognized factor(s) may have contributed to such a discrepancy, it is notable that the studies were not uniform in terms of the antithrombotic regimen provided to the patients (Table 1) It is tempting to speculate that differences in the Pl A2 effect among studies was due to the strength of the antithrombotic regimen. As indicated earlier, we have hypothesized that, to be efficient, an antithrombotic strategy must target a specific susceptibility gene implicated in coronary thrombosis, including thrombotic events that follow stent placement. According to this theory, most Pl A1/A1 patients may find enough protection against adverse events after stent placement from an antithrombotic strategy that includes heparin, ASA (Ն325 mg daily) and a thienopyridine derivative (full dose) for four to six weeks. The Pl A1/A2 heterozygous patients would need the same triple therapy, but a dose of ASA of 160 mg daily might suffice (14) , while the duration of the administration of thienopyridine derivative (clopidogrel, 75 mg daily) might need to be extended for a period of six to 12 months. Whereas the "toughest nuts to crack", the Pl A2/A2 homozygous platelets, may need a GPIIb-IIIa blocker to lower their risk to the level of Pl A1/A1 or Pl A1/A2 patients, in addition to receiving ASA (Ն325 mg daily), clopidogrel (75 mg daily for 6 to 12 months) and heparin. Additional large scale studies will be needed to test the usefulness of stratifying procedural risk with knowledge of Pl A status in patients undergoing catheter based interventions. Considering important issues of safety and increasing cost, it might be of interest not only to stratify risk with genomic information but then target the use of increasingly powerful and costly antithrombotic strategies to those patients who will derive the greatest benefits.
Pl
A2 AND RESTENOSIS
In a previous study of 1,150 consecutive patients with successful coronary stent placements and followed for an average of 163 days, Kastrati et al. (18) A1/A1 homozygous men. The use of stents for coronary interventions has expanded our understanding of the pathophysiology of restenosis, as it has nearly eliminated the component of "recoil" of the vessel wall from the restenotic process. In the presence of a stent, the contribution of neointimal hyperplasia (smooth muscle cell proliferation) to restenosis is more important than after conventional balloon angioplasty. Platelet adhesion and aggregation does contribute substantially to restenosis by promoting the migration and growth of smooth muscle cells (19) . Even when acute stent thrombosis is efficiently prevented in Pl A2 carriers using combination antiplatelet therapy with ASA, heparin and ticlopidine, the residual platelet accumulation might be sufficient to promote restenosis. It may, therefore, be reasonable to extend the duration of the administration of a thienopyridine such as clopidogrel, which causes fewer chronic hematological side effects than ticlopidine, to a full six-month course for patients with the Pl A2 polymorphism. Such genomic-based therapeutic decisions are currently being tested and could have a substantial effect on the efficacy and the cost of antiplatelet therapy in the context of stent placement and restenosis.
Other polymorphisms have been studied in the context of restenosis. The blood level of angiotensin-converting enzyme (ACE) has been linked to an insertion/deletion (I/D) polymorphism of the ACE gene, such that DD genotype carriers have a higher level of ACE than either ID or II. Although, the I/D polymorphism is not associated with restenosis after balloon angioplasty, the D allele is a risk factor for restenosis after coronary stent implantation (20) . In contrast, the HPA-3 polymorphism of platelet GPIIb (Bak) is not associated with an increase in the risk of thrombosis and restenosis over one year after coronary stent placement (21) .
In summary, over the past few years, we have seen an exponential rise of genetic information that may turn out to be of great relevance not only for assessment of risk for individual patients but also for the design of tailored ); †p Ͼ 0.05 for Pl A2 positive patients, whereas OR for stent thrombosis in Pl A2/A2 homozygous patients was 5.1 (p Ͻ 0.05). ASA or acetylsalicylic acid was provided at the indicated daily dose in mg. Ticlid 250 or 500 indicates the daily dose in mg. of ticlopidine used for each study. ACT Ͼ 250 indicates that patients were receiving a dose of heparin sufficient to maintain an activated clotting time (ACT) beyond 250 s. The GPIIb-IIIa-B column refers to patients receiving a GPIIb-IIIa blocker (abciximab).
